|
1.
|
Weiderpass E and Labrèche F: Malignant
tumors of the female reproductive system. Saf Health Work.
3:166–180. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Sharma DN: Radiation in vulvar cancer.
Curr Opin Obstet Gynecol. 24:24–30. 2012. View Article : Google Scholar
|
|
3.
|
Wright JD, Barrena Medel NI, Sehouli J,
Fujiwara K and Herzog TJ: Contemporary management of endometrial
cancer. Lancet. 379:1352–1360. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Willmott LJ and Monk BJ: Cervical cancer
therapy: current, future and anti-angiogensis targeted treatment.
Expert Rev Anticancer Ther. 9:895–903. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
McKenna WG, Weiss MC, Bakanauskas VJ, et
al: The role of the H-ras oncogene in radiation resistance and
metastasis. Int J Radiat Oncol Biol Phys. 18:849–859. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Jones HA, Hahn SM, Bernhard E and McKenna
WG: Ras inhibitors and radiation therapy. Semin Radiat Oncol.
11:328–337. 2001. View Article : Google Scholar
|
|
7.
|
Dar AA, Goff LW, Majid S, Berlin J and
El-Rifai W: Aurora kinase inhibitors-rising stars in cancer
therapeutics? Mol Cancer Ther. 9:268–278. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
O’Neill E and Kolch W: Conferring
specificity on the ubiquitous Raf/MEK signaling pathway. Br J
Cancer. 90:283–288. 2004.PubMed/NCBI
|
|
9.
|
Murphy LO and Blenis J: MAPK signal
specificity: the right place at the right time. Trends Biochem Sci.
31:268–275. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Kohno M and Pouyssegur J: Pharmacological
inhibitors of the ERK signaling pathway: application as anticancer
drugs. Prog Cell Cycle Res. 5:219–224. 2003.PubMed/NCBI
|
|
11.
|
Faivre S, Djelloul S and Raymond E: New
paradigms in anti-cancer therapy: targeting multiple signaling
pathways with kinase inhibitors. Semin Oncol. 33:407–420. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Liu D, Liu Z, Condouris S and Xing M: BRAF
V600E maintains proliferation, transformation, and tumorigenicity
of BRAF-mutant papillary thyroid cancer cells. J Clin Endocrinol
Metab. 92:2264–2271. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Martinelli S, McDowell HP, Vigne SD, Kokai
G, Uccini S and Tartaglia M: RAS signaling dysregulation in human
embryonal rhabdomyosarcoma. Genes Chromosomes Cancer. 48:975–982.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Marshall CJ: The ras oncogenes. J Cell
Sci. 10:157–169. 1998.
|
|
15.
|
Gupta AK, Bakanauskas VJ, Cerniglia GJ, et
al: The Ras radiation resistance pathway. Cancer Res. 61:4278–4282.
2001.PubMed/NCBI
|
|
16.
|
Toulany M, Baumann M and Rodemann HP:
Stimulated PI3K-AKT signaling mediated through ligand or
radiation-induced EGFR depends indirectly, but not directly, on
constitutive K-Ras activity. Mol Cancer Res. 5:863–872. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Adhikary S and Eilers M: Transcriptional
regulation and transformation by Myc proteins. Nat Rev Mol Cell
Biol. 6:635–645. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Mammas IN, Zafiropoulos A and Spandidos
DA: Involvement of the ras genes in female genital tract cancer.
Int J Oncol. 26:1241–1255. 2005.PubMed/NCBI
|
|
19.
|
Carmena M and Earnshaw WC: The cellular
geography of aurora kinases. Nat Rev Mol Cell Biol. 4:842–854.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Ducat D and Zheng Y: Aurora kinases in
spindle assembly and chromosome segregation. Exp Cell Res.
301:60–67. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Marumoto T, Zhang D and Saya H: Aurora A,
a guardian of poles. Nat Rev Cancer. 5:42–50. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Fu J, Bian M, Jiang Q and Zhang C: Roles
of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res.
5:1–10. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Kobayashi M, Nakamura S, Ono T, et al:
Analysis of aurora kinase expressions and cell cycle regulation by
Aurora C in leukemia cells. Blood (ASH Annual Meeting Abstracts).
108:13662006.
|
|
24.
|
Slattery SD, Mancini MA, Brinkley BR and
Hall RM: Aurora-C kinase supports mitotic progression in the
absence of Aurora-B. Cell Cycle. 8:2986–2997. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Zhang X: Aurora kinases. Curr Biol.
18:R146–R148. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Carvajal RD, Tse A and Schwartz GK: Aurora
kinases: new targets for cancer therapy. Clin Cancer Res.
12:6869–6875. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Girdler F, Gascoigne KE, Eyers PA, et al:
Validating Aurora B as an anti-cancer drug target. J Cell Sci.
119:3664–3675. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Smith SL, Bowers NL, Betticher DC, et al:
Overexpression of Aurora B kinase (AURBK) in primary non-small cell
lung carcinoma is frequent, generally driven from one allele, and
correlates with the level of genetic instability. Br J Cancer.
93:719–729. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Gautschi O, Heighway J, Mack PC, Purnell
PR, Lara PN Jr and Gandara DR: Aurora kinases as anticancer drug
targets. Clin Cancer Res. 14:1639–1648. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Keen M and Taylor S: Mitotic drivers -
inhibitors of the Aurora B kinase. Cancer Metastasis Rev.
28:185–195. 2009. View Article : Google Scholar
|
|
31.
|
Bonet C, Giuliano S, Ohanna M, et al:
Aurora B is regulated by the mitogen-activated protein
kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling
pathway and is a valuable potential target in melanoma cells. J
Biol Chem. 287:29887–29898. 2012. View Article : Google Scholar
|
|
32.
|
Marampon F, Gravina GL, Di Rocco A, et al:
MEK/ERK inhibitor U0126 increases the radiosensitivity of
rhabdomyosarcoma cells in vitro and in vivo by downregulating
growth and DNA repair signals. Mol Cancer Ther. 10:159–168. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Marampon F, Bossi G, Ciccarelli C, et al:
MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of
embryonal rhabdomyosarcoma. Mol Cancer Ther. 8:543–551. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Marampon F, Ciccarelli C and Zani BM:
Down-regulation of c-Myc following MEK/ERK inhibition halts the
expression of malignant phenotype in rhabdomyosarcoma and in non
muscle-derived human tumors. Mol Cancer. 5:312009. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Allalunis-Turner MJ, Zia PK, Barron GM,
Mirzayans R and Day RS III: Radiation-induced DNA damage and repair
in cells of a radiosensitive human malignant glioma cell line.
Radiat Res. 144:288–293. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Lees-Miller SP, Godbout R, Chan DW,
Weinfeld M, Day RS III, Barron GM and Allalunis-Turner J: Absence
of p350 subunit of DNA-activated protein kinase from a
radiosensitive human cell line. Science. 267:1183–1185. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Tian X, Chen G, Xing H, Weng D, Guo Y and
Ma D: The relationship between the down-regulation of DNA-PKcs or
Ku70 and the chemosensitization in human cervical carcinoma cell
line HeLa. Oncol Rep. 18:927–932. 2007.PubMed/NCBI
|
|
38.
|
Gerweck LE, Vijayappa S, Kurimasa A, Ogawa
K and Chen DJ: Tumor cell radiosensitivity is a major determinant
of tumor response to radiation. Cancer Res. 66:8352–8355. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
van Gent DC, Hoeijmakers JH and Kanaar R:
Chromosomal stability and the DNA double-stranded break connection.
Nat Rev Genet. 2:196–206. 2001.
|
|
40.
|
Lowry OH, Rosebrough NJ, Farr AL and
Randall RJ: Protein measurement with the Folin phenol reagent. Biol
Chem. 193:265–275. 1951.PubMed/NCBI
|
|
41.
|
Mori S, Chang JT, Andrechek ER, et al:
Anchorage-independent cell growth signature identifies tumors with
metastatic potential. Oncogene. 28:2796–2805. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Sak A, Stuschke M, Groneberg M, Kübler D,
Pöttgen C and Eberhardt WE: Inhibiting the Aurora B kinase potently
suppresses repopulation during fractionated irradiation of human
lung cancer cell lines. Int J Radiat Oncol Biol Phys. 84:492–499.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Borges KS, Castro-Gamero AM, Moreno DA, et
al: Inhibition of Aurora kinases enhances chemosensitivity to
temozolomide and causes radiosensitization in glioblastoma cells. J
Cancer Res Clin Oncol. 138:405–414. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Niermann KJ, Moretti L, Giacalone NJ, et
al: Enhanced radiosensitivity of androgen-resistant prostate
cancer: AZD1152-mediated Aurora kinase B inhibition. Radiat Res.
175:444–451. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Kosik A, Bekier ME, Katusin JD, et al:
Investigating the role of Aurora kinases in RAS signaling. J Cell
Biochem. 106:33–41. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Ma Y, Weimer J, Fredrik R, et al: Aurora
kinase inhibitor AZD1152 has an additional effect of platinum on a
sequential application at the human ovarian cancer cell line SKOV3.
Arch Gynecol Obstet. 288:173–182. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Baldini E, Sorrenti S, D’Armiento E, et
al: Aurora kinases: new molecular targets in thyroid cancer
therapy. Clin Ter. 163:e457–462. 2012.PubMed/NCBI
|
